NCT02765724View on ClinicalTrials.gov

Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Myelofibrosis
Interventions
DRUG

Pacritinib

Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration

Trial Locations (2)

D-81241

APEX GmbH, Munich

MD-2025

Republican Clinical Hospital, Chisinau

Sponsors

Lead Sponsor

CTI BioPharma
All Listed Sponsors
collaborator

SGS S.A.

INDUSTRY

lead

CTI BioPharma

INDUSTRY